OptiBiotix Health PLC SweetBiotix® development: Results of taste study (6258K)
July 11 2017 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 6258K
OptiBiotix Health PLC
11 July 2017
11 July 2017
OptiBiotix Health plc
("OptiBiotix" or the Company")
SweetBiotix(R) development: Results of human taste study
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, announces successful human taste
studies in its SweetBiotix(R) product development programme. The
programme has been designed to develop sweet natural healthy
fibres, called SweetBiotix(R) , which are not digested in the human
gut, and hence calorie free.
The study was carried out by The Flavour and Sensory Science
Centre at the University of Reading who tested six customised
oligosaccharides developed from high intensity sweeteners which
were compared to sucrose. The study used a trained expert panel of
ten experienced panellists and showed:-
-- The customised oligosaccharides showed sweetness of between
140X and 223X that of sucrose at equivalent concentrations
-- Customised oligosaccharides derived from Stevia showed a
large reduction in bitterness whilst not affecting its
sweetness
The results of this independent study provide proof of product
concept for a natural, low calorie, SweetBiotix(R). This is an
innovative concept which has the potential to address public health
concerns over the impact of sugar on obesity, with the prospect of
replacing 'unhealthy' sugars in existing products with low calorie,
healthy non-digestible fibres, trademarked as SweetBiotix(R).
Given the global sweetener market, currently dominated by sugar,
is forecast to reach $112bn by 2022 (Mordor Intelligence, 2017),
the Company are filing additional patents to add a further layer of
protection to the existing intellectual property portfolio to
protect their inventions and fully exploit the commercial
potential.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are really
pleased with the results of this study which opens up opportunities
for the development of a range of natural sweet prebiotic fibres
which can be used to replace sugar in food and beverages. These may
be classified as dietary fibres, which from an industry and
consumer perspective, creates the prospect of substituting high
calorie sugars with sweet healthy fibres. With growing public and
political concerns over traditional sugars and artificial
sweeteners OptiBiotix is leading research in an area of growing
industry interest."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESZBLFFDDFBBBX
(END) Dow Jones Newswires
July 11, 2017 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024